Bharat Biotech’s COVAXIN got approval for the second-phase trial for the age group 2-18

12 May 2021

Bharat Biotech’s COVAXIN got approval for the second-phase trial for the age group 2-18

Bharat Biotech India’s one of the leading vaccine manufacturers got approval from the govt of India for the second phase trial of its vaccine for the age group 2-18 years. To date, we have vaccines for the 18+age group in India and it is assumed that the coming third wave of coronavirus would be dangerous for the under 18 population as the rest will get at least one dose of the vaccine either by COVISHIELD or COVAXIN. According to data 2% of India’s adult population is fully vaccinated while 13% got at least one jab of it.